Pembrolizumab with chemotherapy for platinum-resistant recurrent ovarian cancer after 1 or 2 therapies

Pembrolizumab in combination with paclitaxel with or without bevacizumab is in clinical development for the treatment of platinum-resistant recurrent ovarian cancer after one or two prior therapies. Ovarian cancer occurs when abnormal cells in the ovary begin to grow and divide in an uncontrolled way to eventually form a growth (tumour). Some of the symptoms include bloating or a swollen tummy, discomfort in the tummy or pelvic area, and a frequent urge to urinate. Ovarian cancer has poor survival rates due to a combination of late diagnosis and disease recurrence owing to platinum chemotherapy resistance. While there are therapeutic advances in ovarian cancer generally, platinum-resistant recurrent ovarian cancer remains an area of high unmet clinical need and new treatments to further improve clinical outcomes are needed.